Free Trial
NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

VolitionRx logo
$0.48 -0.03 (-6.01%)
As of 05/27/2025 04:10 PM Eastern

About VolitionRx Stock (NYSEAMERICAN:VNRX)

Key Stats

Today's Range
$0.48
$0.53
50-Day Range
$0.42
$0.57
52-Week Range
$0.40
$0.90
Volume
219,051 shs
Average Volume
182,123 shs
Market Capitalization
$30.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
VolitionRX Q1 2025 Earnings Preview
See More Headlines

VNRX Stock Analysis - Frequently Asked Questions

VolitionRx's stock was trading at $0.58 at the beginning of 2025. Since then, VNRX shares have decreased by 16.5% and is now trading at $0.4845.
View the best growth stocks for 2025 here
.

VolitionRx Limited (NYSEAMERICAN:VNRX) issued its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company earned $0.03 million during the quarter, compared to analysts' expectations of $0.03 million. VolitionRx had a negative trailing twelve-month return on equity of 15,493.47% and a negative net margin of 9,158.31%.

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Exelixis (EXEL), T2 Biosystems (TTOO) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/10/2021
Today
5/27/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.27 million
Net Margins
-9,158.31%
Pretax Margin
-9,257.43%
Return on Equity
-15,493.47%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-9.69

Miscellaneous

Free Float
53,450,000
Market Cap
$30.61 million
Optionable
Not Optionable
Beta
1.59
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSEAMERICAN:VNRX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners